Results 51 to 60 of about 182,500 (270)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Copine‐4 Paraneoplastic Autoimmune Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We characterize copine‐4 (CPNE4)‐IgG and report clinical associations. Among 844 samples with unclassified neural IgGs identified by mouse‐brain indirect immunofluorescence assay over 2 years, 5 samples (serum, 3; CSF, 2) from 3 patients produced a distinctive cerebrum‐restricted synaptic pattern.
Mimi S. Fang   +12 more
wiley   +1 more source

Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis

open access: yesFrontiers in Immunology
IntroductionThis systematic review and network meta-analysis(NMA) was designed to compare the long-term outcomes of pembrolizumab monotherapy and pembrolizumab plus chemotherapy as first-line therapy for metastatic non-small-cell lung cancer(NSCLC ...
Shibo Huang   +5 more
doaj   +1 more source

Spotlight on pembrolizumab in the treatment of advanced melanoma [PDF]

open access: yes, 2015
Thanashan Rajakulendran,1 David N Adam2 1Department of Medicine, Division of Dermatology, Postgraduate Medical Education, 2Department of Medicine, Division of Dermatology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada ...
Rajakulendran T, Adam DN
core  

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

open access: yesAdvanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin   +20 more
wiley   +1 more source

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

open access: yesAdvanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu   +18 more
wiley   +1 more source

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

open access: yesBMC Cancer
Background Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits compared with single-agent ...
Byoung Chul Cho   +13 more
doaj   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

open access: yesAdvanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu   +7 more
wiley   +1 more source

A Physicochemical Stability Study of Pembrolizumab Vial Leftovers: Let Us Stop Pouring Good Money Down the Drain

open access: yesPharmacy
Background: Pembrolizumab is a monoclonal antibody (mAb) approved for treating Non-Small Cell Lung Cancer (NSCLC), melanoma and lymphomas. Commercialized in single-size (100 mg/4 mL) vials, the pembrolizumab solution contains no preservative.
Alexandra Porlier   +7 more
doaj   +1 more source

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

open access: yesAdvanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy